CASI Pharmaceuticals, Inc.
CASIF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001962738
No open-market purchases or sales by CASI Pharmaceuticals, Inc. insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $17 in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding CASI Pharmaceuticals, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 21 | 19 | −2 |
| Shares | 929.8K | 449.9K | −479.9K (−51.6%) |
| Value | $2.15M | $1.12M | −$1.03M (−47.8%) |
New holders (2)
Institutions that held CASI Pharmaceuticals, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 28,162 | $70.4K | 0.00% |
| Fiduciary Alliance LLC | 30 | $75 | 0.00% |
Sold out (4)
Institutions that held CASI Pharmaceuticals, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Susquehanna International Group, LLP | 38,326 | $88.2K |
| State Street Corp | 35,555 | $81.8K |
| Dimensional Fund Advisors LP | 11,508 | $26.5K |
| UBS Group AG | 6,175 | $14.3K |